Advances in real-world evidence (RWE) have dramatically expanded its influence on clinical guidelines, regulatory decisions, and health system policies worldwide. As the volume and rigor of RWE increase, translating these insights into tangible healthcare improvements remains a complex challenge—requiring not only scientific excellence but also effective collaboration and communication among diverse stakeholders.

Despite significant progress, persistent barriers remain. Converting nuanced, context-rich real-world data (RWD) into RWE which informs policies that are both responsive and sustainable often necessitates aligning competing priorities and demonstrating relevance in domains traditionally dominated by randomized controlled trials. The most compelling examples—where RWE has facilitated regulatory approvals, updated clinical guidelines, or influenced reimbursement decisions—highlight both the potential and complexity of translating RWD into real-world impact.

This presentation will illustrate how RWE has driven meaningful policy and practice changes, showcasing key case studies. Drawing on her leadership and experience, Dr. Ritchey will share practical strategies for overcoming translational barriers. She will emphasize the importance of stakeholder engagement, methodologic transparency, and ongoing dialogue between RWD holders, RWE generators, and decision-makers.

By reflecting on both successes and ongoing challenges, this session aims to equip RWE professionals with insights and strategies to accelerate the translation of data into improved patient outcomes and public health. Ultimately, it demonstrates how real-world research can be a powerful catalyst for sustained, meaningful change in generating actionable evidence for medical products.